Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

PTCy versus ATG in HLA-matched sibling donor allogeneic transplantation: Comment on: Improved GVHD-free relapse-free survival when rATG/ATLG is used in allo-HCT from matched sibling donors - an EBMT registry study by the Transplant Complications Working Party

Bone Marrow Transplantation (2026)Cite this article

Subjects

To the Editor

We read with interest the European Society for Blood and Marrow Transplantation (EBMT) registry analysis by Piekarska et al. on the use of rabbit anti-thymocyte/anti-T-lymphocyte globulin (rATG/ATLG) in matched sibling donor (MSD) hematopoietic stem cell transplantation (HSCT), which demonstrated improved 2-year GVHD-free, relapse-free survival (GRFS) [40.7% vs. 32.2%, p < 0.001] with the addition of ATG [1]. While the study is commendable for its large cohort size and comprehensive analysis, certain aspects merit further consideration in light of the rapidly evolving landscape of GVHD prophylaxis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Piekarska A, Abouqateb M, Boreland W, Peczynski C, Zaucha JM, Kröger N, et al. Improved GVHD-free relapse-free survival when rATG/ATLG is used in allo-HCT from matched sibling donors - an EBMT registry study by the Transplant Complications Working Party. Bone Marrow Transplant. 2025;60:1574–83.

  2. Zand MS, Vo T, Pellegrin T, Felgar R, Liesveld JL, Ifthikharuddin JJ, et al. Apoptosis and complement-mediated lysis of myeloma cells by polyclonal rabbit antithymocyte globulin. Blood. 2006;107:2895–903.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Desai N, Rodriguez-Rodriguez S, Al-Shaibani E, Alfaro Moya T, Law AD, Novitzky-Basso I, et al. A decade of experience using ATG and PTCy for graft-versus-host disease prophylaxis in matched unrelated donor allogeneic haematopoietic cell transplantation. Br J Haematol. 2025;207:2049–58.

  4. Remberger M, Ringdén O, Hägglund H, Svahn BM, Ljungman P, Uhlin M, et al. A high antithymocyte globulin dose increases the risk of relapse after reduced intensity conditioning HSCT with unrelated donors. Clin Transplant. 2013;27:E368–74.

    Article  CAS  PubMed  Google Scholar 

  5. Bolaños-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, et al. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. N Engl J Med. 2023;388:2338–48.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Desai N, Altareb M, Remberger M, Chen C, Alfaro Moya T, Al-Shaibani E, et al. PTCy-based graft-versus-host disease prophylaxis for matched sibling donor allogeneic hematopoietic cell transplantation. Blood Adv. 2025;9:660–9.

  7. Desai N, Mattsson J, Law AD. Cyclophosphamide and Cyclosporin for GVHD Prevention. N Engl J Med. 2025;393:1349–50.

    Article  PubMed  Google Scholar 

  8. Curtis DJ, Patil SS, Reynolds J, Purtill D, Lewis C, Ritchie DS, et al. Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin. N Engl J Med. 2025;393:243–54.

  9. Walker I, Panzarella T, Couban S, Couture F, Devins G, Elemary M, et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncol. 2016;17:164–73.

    Article  CAS  PubMed  Google Scholar 

  10. Zuckermann J, Castro BM, Cunha TA, Paz A, Moreira LB. Systematic review and meta-analysis of anti-thymocyte globulin dosage as a component of graft-versus-host disease prophylaxis. PLoS One. 2023;18:e0284476.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Desai N, Althobaiti M, Alfaro-Moya T, Al-Shaibani E, Novitzky-Basso I, Pasic I, et al. Reduced dose PTCy in patients with acute myeloid leukemia receiving matched unrelated donor allogeneic hematopoietic stem cell transplantation. JCO. 2025;43:6511.

    Article  Google Scholar 

  12. Juárez A, Salas MQ, Pedraza A, Suárez-Lledó M, Rodríguez-Lobato LG, Solano MT, et al. Reduced Dose of Post-Transplant Cyclophosphamide with Tacrolimus for the Prevention of Graft-versus-Host Disease in HLA-Matched Donor Peripheral Blood Stem Cell Transplants: A Prospective Pilot Study. Cancers (Basel). 2024;16:2567.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hans Messner Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Center, University Health Network, Toronto, Canada

    Nihar Desai & Auro Viswabandya

  2. Temerty Faculty of Medicine, University of Toronto, Toronto, Canada

    Nihar Desai & Auro Viswabandya

Authors
  1. Nihar Desai
    View author publications

    Search author on:PubMed Google Scholar

  2. Auro Viswabandya
    View author publications

    Search author on:PubMed Google Scholar

Contributions

ND and AV wrote the first draft of the manuscript and approved the final version.

Corresponding author

Correspondence to Auro Viswabandya.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Desai, N., Viswabandya, A. PTCy versus ATG in HLA-matched sibling donor allogeneic transplantation: Comment on: Improved GVHD-free relapse-free survival when rATG/ATLG is used in allo-HCT from matched sibling donors - an EBMT registry study by the Transplant Complications Working Party. Bone Marrow Transplant (2026). https://doi.org/10.1038/s41409-026-02799-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Version of record:

  • DOI: https://doi.org/10.1038/s41409-026-02799-z

Search

Advanced search

Quick links